Logo image
Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis
Journal article   Open access   Peer reviewed

Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis

Poyil Pratheeshkumar, Young-Ok Son, Amit Budhraja, Xin Wang, Songze Ding, Lei Wang, Andrew Hitron, Jeong-Chae Lee, Donghern Kim, Sasidharan Padmaja Divya, …
PloS one, Vol.7(12), pp.e52279-e52279
2012
DOI: 10.1371/journal.pone.0052279
PMCID: PMC3534088
PMID: 23300633
url
https://doi.org/10.1371/journal.pone.0052279View
Published (Version of record) Open Access

Abstract

Angiogenesis, the formation of new blood vessels from pre-existing vascular beds, is essential for tumor growth, invasion, and metastasis. Luteolin is a common dietary flavonoid found in fruits and vegetables. We studied the antiangiogenic activity of luteolin using in vitro, ex vivo, and in vivo models. In vitro studies using rat aortic ring assay showed that luteolin at non-toxic concentrations significantly inhibited microvessel sprouting and proliferation, migration, invasion and tube formation of endothelial cells, which are key events in the process of angiogenesis. Luteolin also inhibited ex vivo angiogenesis as revealed by chicken egg chorioallantoic membrane assay (CAM) and matrigel plug assay. Gelatin zymographic analysis demonstrated the inhibitory effect of luteolin on the activation of matrix metalloproteinases MMP-2 and MMP-9. Western blot analysis showed that luteolin suppressed VEGF induced phosphorylation of VEGF receptor 2 and their downstream protein kinases AKT, ERK, mTOR, P70S6K, MMP-2, and MMP-9 in HUVECs. Proinflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α level were significantly reduced by the treatment of luteolin in PC-3 cells. Luteolin (10 mg/kg/d) significantly reduced the volume and the weight of solid tumors in prostate xenograft mouse model, indicating that luteolin inhibited tumorigenesis by targeting angiogenesis. CD31 and CD34 immunohistochemical staining further revealed that the microvessel density could be remarkably suppressed by luteolin. Moreover, luteolin reduced cell viability and induced apoptosis in prostate cancer cells, which were correlated with the downregulation of AKT, ERK, mTOR, P70S6K, MMP-2, and MMP-9 expressions. Taken together, our findings demonstrate that luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Animals Aorta - drug effects Aorta - physiology Cell Line, Tumor Cell Movement - drug effects Cell Proliferation - drug effects Cell Survival - drug effects Chick Embryo Chorioallantoic Membrane - drug effects Cytokines - biosynthesis Extracellular Signal-Regulated MAP Kinases - metabolism Human Umbilical Vein Endothelial Cells - cytology Human Umbilical Vein Endothelial Cells - drug effects Humans In Vitro Techniques Luteolin - pharmacology Luteolin - therapeutic use Male Matrix Metalloproteinases - metabolism Mice Microvessels - drug effects Microvessels - physiology Neoplasm Invasiveness Neovascularization, Pathologic - drug therapy Prostatic Neoplasms - blood supply Prostatic Neoplasms - pathology Proto-Oncogene Proteins c-akt - metabolism Rats Ribosomal Protein S6 Kinases, 70-kDa - metabolism Signal Transduction - drug effects TOR Serine-Threonine Kinases - metabolism Vascular Endothelial Growth Factor Receptor-2 - metabolism Xenograft Model Antitumor Assays

Details

Metrics

Logo image